The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
Numbers of T-cell subtypes at six time points in patients with newly diagnosed HGGs undergoing standard RT/TMZ and adjuvant TMZ: 1. Baseline within 2 weeks before initiation of RT/TMZ 2. At the end of RT/TMZ approximately week 6 3. Before adjuvant TMZ approximately week 10 4. After 2 cycle of TMZ approximately week 18 5. After 4 cycle of TMZ approximately week 26 6. Three month after last cycle of TMZ Secondary Endpoints 1. Changes in serial T cell subtypes and cytokines levels 2. Incidence of lymphopenia related infections 3. Changes in T-cell numbers and subtypes with TMZ administration 4. Overall survival
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
20
pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
Johns Hopkins
Baltimore, Maryland, United States
Washington University
St Louis, Missouri, United States
Changes in T Cell subtypes and cytokines as a function of treatment
baseline approx 6wks approx 10wks aprox 18wks approx 26wks 3 months after last cycle of TMZ
Time frame: 6 time points in pts undergoing standard RT/TMZ and adjuvant TMZ
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.